SIGA Technologies Inc. - Q1 2011 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2011. SIGA Technologies, Inc. is a biopharmaceutical company focused on the research and development of novel products for the prevention and treatment of serious infectious diseases, including biological warfare agents. The company's lead product candidate is ST-246, an antiviral drug targeting orthopoxviruses (smallpox). The company currently has no commercial products and relies on government grants and contracts for funding.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Revenue (Research & Development Grants) | $1,696,721 | $5,075,211 |
| Operating Expenses | $8,158,161 | $8,116,153 |
| Operating Loss | $(6,461,440) | $(3,040,942) |
| Net Loss | $(4,701,275) | $(4,937,128) |
| Net Loss Per Share (Basic & Diluted) | $(0.09) | $(0.11) |
| Cash and Cash Equivalents (End of Period) | $3,835,915 | $8,508,027 |
| Short-Term Investments | $14,999,550 | $14,999,350 |
| Total Current Assets | $20,423,847 | $24,702,564 |
| Total Current Liabilities | $3,286,176 | $4,263,180 |
| Warrant Liability (Fair Value) | $7,790,886 | $10,524,660 |
Cash Flow: Net cash used in operating activities was $4.3 million. Net cash provided by financing activities was $1.8 million, primarily from the exercise of warrants and options.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately $3.4 million (66%) compared to Q1 2010. This was primarily due to a $3.2 million decrease in federal grant revenue supporting ST-246 development and the conclusion of grants related to Lassa fever.
- Expense Shifts: While total operating expenses remained relatively flat, the composition changed. Selling, General, and Administrative (SG&A) expenses increased by $2.3 million, driven by higher employee compensation (including $961,000 in stock-based compensation) and a $722,000 increase in legal fees. Conversely, R&D expenses decreased by $2.2 million, largely due to reduced expenditures on ST-246 development.
- Warrant Valuation Gain: The company recorded a non-cash gain of $1.8 million due to a decrease in the fair value of common stock warrants, compared to a $1.9 million loss in the prior year. This significantly reduced the reported net loss.
- Liquidity: Cash and cash equivalents decreased by approximately $2.5 million during the quarter, though total liquid assets (cash plus short-term investments) remained stable at roughly $18.8 million.
Outlook, Risks, and Management Commentary
- Funding and Grants: Management expects existing funds and continuing government grants to support operations for at least the next 12 months. On May 3, 2011 (post-period), the company was awarded a $6.5 million grant from NIAID for dengue virus development. However, a $2.8 million DTRA contract is expected to conclude in Q2 2011 with no option exercises.
- BARDA Smallpox Contract: The 2009 BARDA Smallpox RFP was cancelled in February 2011. A new RFP for 1.7 million courses of smallpox antiviral was issued, to which SIGA has responded. There is no assurance of an award.
- Legal Contingency: The company is involved in ongoing litigation with PharmAthene, Inc. regarding ST-246 licensing. PharmAthene seeks damages up to $1 billion. A trial concluded in January 2011 with closing arguments in April 2011. Management believes it has meritorious defenses but cannot estimate a range of loss.
- Development Costs: Estimated costs to complete ST-246 development for adult therapeutic use are projected at $15 million to $20 million over the next 24 months.
- Risk Factors: The company faces risks related to the failure of clinical trials, inability to secure future funding, regulatory delays, and the outcome of the PharmAthene litigation.
Investor Verification Checklist
- Grant Dependency: Verify the status and renewal likelihood of the $60.8 million in remaining grant funding, specifically the new NIAID grant and the outcome of the new BARDA RFP.
- Legal Exposure: Monitor the final ruling in the PharmAthene, Inc. v. SIGA Technologies, Inc. case, given the potential $1 billion damages claim.
- Cash Burn Rate: Assess the sustainability of the current cash position ($3.8 million cash + $15 million short-term investments) against the projected $15-$20 million needed to complete ST-246 development.
- Warrant Liability: Note that the $7.8 million warrant liability is a non-cash fair value adjustment that can cause significant volatility in reported net income/loss.
- Revenue Recognition: Confirm the timing of revenue recognition from government contracts, as the Q1 2011 revenue drop was significant compared to the prior year.